Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 3
2016 3
2017 2
2018 1
2019 4
2020 6
2021 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Rovin BH, et al. Among authors: arriens c. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Lancet. 2021. PMID: 33971155 Clinical Trial.
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Saxena A, et al. Among authors: arriens c. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15. Arthritis Rheumatol. 2024. PMID: 37466424
Ancestry-based differences in the immune phenotype are associated with lupus activity.
Slight-Webb S, Thomas K, Smith M, Wagner CA, Macwana S, Bylinska A, Donato M, Dvorak M, Chang SE, Kuo A, Cheung P, Kalesinskas L, Ganesan A, Dermadi D, Guthridge CJ, DeJager W, Wright C, Foecke MH, Merrill JT, Chakravarty E, Arriens C, Maecker HT, Khatri P, Utz PJ, James JA, Guthridge JM. Slight-Webb S, et al. Among authors: arriens c. JCI Insight. 2023 Aug 22;8(16):e169584. doi: 10.1172/jci.insight.169584. JCI Insight. 2023. PMID: 37606045 Free PMC article.
Cell-bound complement activation products associate with lupus severity in SLE.
Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Arriens C, et al. Lupus Sci Med. 2020 Apr;7(1):e000377. doi: 10.1136/lupus-2019-000377. Lupus Sci Med. 2020. PMID: 32371480 Free PMC article.
A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus.
Munroe ME, Blankenship D, DeFreese D, Purushothaman M, DeJager W, Macwana S, Guthridge JM, Kamp S, Redinger N, Aberle T, Chakravarty EF, Arriens C, Li Y, Zeng H, McCarthy-Fruin KA, Osei-Onomahm SA, Thanarajasingam U, James JA, Jupe E. Munroe ME, et al. Among authors: arriens c. Arthritis Rheumatol. 2023 May;75(5):723-735. doi: 10.1002/art.42389. Epub 2023 Mar 6. Arthritis Rheumatol. 2023. PMID: 36245261 Free PMC article.
28 results